SCHEMBL766989

SCHEMBL766989

O=C(Nc1ccccc1)c1ccc(Cl)c(Br)c1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPD1 P10809 1/20 0.54
HSPE1 P61604 1/20 0.54
MEN1 O00255 6/20 0.51
KMT2A Q03164 6/20 0.51
LMNA P02545 2/20 0.51
TP53 P04637 2/20 0.51
HPGD P15428 2/20 0.51
HTT P42858 2/20 0.51
KDM4E B2RXH2 1/20 0.51
HSD17B10 Q99714 1/20 0.51
TMPRSS4 Q9NRS4 1/20 0.51
BDKRB1 P46663 1/20 0.49
MAPT P10636 4/20 0.49
CYP2C19 P33261 3/20 0.49
PPARG P37231 2/20 0.49
MAPK1 P28482 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2D6 P10635 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3441192 0.84 HSPD1 (0.60) HSPD1HSPE1MEN1KMT2ALMNA
SCHEMBL28091035 0.84 GPR27 (0.57) MEN1KMT2ALMNATP53HPGD
SCHEMBL766990 0.81 HSPD1 (0.57) HSPD1HSPE1MEN1KMT2ALMNA
SCHEMBL2169634 0.81 MEN1 (0.68) HSPD1HSPE1MEN1KMT2ALMNA
SCHEMBL5852388 0.79 KLKB1 (0.72) MEN1KMT2ALMNATP53HPGD
SCHEMBL27754113 0.77 KMT2A (0.61) MEN1KMT2ALMNATP53HPGD
SCHEMBL229763 0.76 HSPD1 (0.68) HSPD1HSPE1MEN1KMT2ALMNA
SCHEMBL29474808 0.76 HSPD1 (0.68) HSPD1HSPE1MEN1KMT2ALMNA
SCHEMBL7067826 0.76 MEN1 (0.71) HSPD1HSPE1MEN1KMT2ALMNA
SCHEMBL8052698 0.76 KMT2A (0.69) HSPD1HSPE1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260091043-A1 COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIUM INFECTIONS DATA2DISCOVERY INC (US) 2026-04-02 US claimed
US-12274830-B2 Nitric oxide inhalation therapy for infants with bronchiolitis BEYOND AIR LTD (IL) 2025-04-15 US claimed
US-20240173512-A1 METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS STREETERVILLE CAPITAL, LLC 2024-05-30 US claimed
WO-2024064209-A1 COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIUM INFECTIONS DATA2DISCOVERY, INC. (US) 2024-03-28 WO claimed
US-11890421-B2 Methods for potentiating antimicrobial agents BEYOND AIR LTD (IL) 2024-02-06 US claimed
WO-2022040799-A1 ANTIMICROBIAL COMPOSITION GP TECH INOVASYON TEKNOLOJI VE ARASTIRMA A.S (TR) 2022-03-03 WO claimed
EP-3927334-A1 NONHORMONAL UNISEX CONTRACEPTIVES The Regents of The University of California (US) 2021-12-29 EP claimed
US-20210369652-A1 Nonhormonal Unisex Contraceptives THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-12-02 US claimed
US-11166926-B2 Compositions and methods for protecting a host from enteric toxigenic pathogens THE HOSPITAL FOR SICK CHILDREN (CA) 2021-11-09 US claimed
CN-113453673-A Non-hormone contraceptive for both men and women 加利福尼亚大学董事会 2021-09-28 CN claimed
US-20090215888-A1 TOPICAL NAIL FORMULATION NUVO RESEARCH INC. (CA) 2009-08-27 US claimed
WO-2007098591-A2 TOPICAL NAIL FORMULATION NUVO RESEARCH INC. (CA) 2007-09-07 WO claimed
US-7198800-B1 Compositions and methods Ko, Thomas Sai Ying (CN) 2007-04-03 US claimed
EP-1696855-A1 DERMAL DRUG DELIVERY SYSTEM Medpharm Limited (GB) 2006-09-06 EP claimed
US-20060130266-A1 Dermal drug delivery system MEDPHARM LIMITED (GB) 2006-06-22 US claimed
WO-2005058226-A1 DERMAL DRUG DELIVERY SYSTEM MEDPHARM LIMITED (GB) 2005-06-30 WO claimed
JP-2003514875-A 2003-04-22 JP claimed
EP-1231948-A1 A PROPELLANT FREE SPRAY-ON SKIN PATCH COMPOSITION FOR IMPROVING WOUND HEALING AND FOR DRUG ADMINISTRATION Ever Power Holding Inc. (VG) 2002-08-21 EP claimed
WO-2001037890-A1 A PROPELLANT FREE SPRAY-ON SKIN PATCH COMPOSITION FOR IMPROVING WOUND HEALING AND FOR DRUG ADMINISTRATION EVER POWER HOLDING INC (VG) 2001-05-31 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260091043-A1 COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIUM INFECTIONS AHCY, MACO1, ME3 HSPD1 1087/4885HSPE1 1950/4885MEN1 2966/4885
US-20210369652-A1 Nonhormonal Unisex Contraceptives UQCRC1, UQCRC2, MCU HSPD1 90/4885HSPE1 58/4885MEN1 2175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.